@inbook{103201,
  keywords = {Tuberculosis, Drugs, leprosy},
  author = {Jawahar M and Banu Rekha V},
  title = {Drugs used in tuberculosis and leprosy},
  abstract = {<p>This review of the 2010 publications on drugs used in tuberculosis and leprosy covers&nbsp;dapsone,&nbsp;ethambutol, isoniazid, pyrazinamide, rifampicin, and&nbsp;rifaximin, and there is a special review on hepatotoxicity of&nbsp;antituberculosis drugs.&nbsp;Adverse reactions&nbsp;involving the nervous system and the effects of&nbsp;glucocorticoids&nbsp;on vision and ocular complications in patients with ocular tuberculosis are discussed. Drug-induced hepatotoxicity has been reported in relation to genetic polymorphisms in&nbsp;glutathione&nbsp;S-transferase and&nbsp;NAT2&nbsp;acetylator status. In a retrospective study of drug-induced liver damage in liver transplant recipients in the USA, antituberculosis drugs were responsible for 8–9% of cases.&nbsp;Methemoglobinemia&nbsp;in patients taking dapsone continues to be reported. The risk of&nbsp;autosomal dominant optic atrophy&nbsp;is related to polymorphisms in the OPA1 gene. Rifaximin appears to be more effective than either placebo or&nbsp;lactulose&nbsp;in reducing the risk of recurrence of&nbsp;hepatic encephalopathy&nbsp;with few adverse reactions.</p>
},
  year = {2012},
  journal = {Side Effects of Drugs Annual},
  pages = {479-486},
  publisher = {Elsevier},
  issn = {0378-6080},
  doi = {10.1016/b978-0-444-59499-0.00030-1},
  language = {ENG},
}